Obesity and cardiovascular thrombotic events in patients undergoing percutaneous coronary intervention with drug-eluting stents

Heart

Volumn 95, Issue 19, 2009, Pages 1587-1592

  Wang, Z J ^a   Zhou, Yu Jie ^a   Liu, Y Y ^a   Yu, M ^a   Shi, D M ^a   Zhao, Y X ^a   Guo, Y H ^a   Cheng, W J ^a   Nie, B ^a   Ge, H L ^a   Jia, D A ^a   Yang, S W ^a   Yan, Z X ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; ARTICLE; BODY MASS; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HUMAN; INCIDENCE; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OBESITY; PATIENT COMPLIANCE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; ST SEGMENT ELEVATION; STENT THROMBOSIS; THROMBOSIS; TREATMENT OUTCOME;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ASPIRIN; BLOOD VESSEL PROSTHESIS; BODY MASS INDEX; CORONARY DISEASE; DEATH, SUDDEN, CARDIAC; DRUG-ELUTING STENTS; FEMALE; GRAFT OCCLUSION, VASCULAR; HUMANS; MALE; MIDDLE AGED; OBESITY; PLATELET AGGREGATION INHIBITORS; RETROSPECTIVE STUDIES; THROMBOSIS; TICLOPIDINE;

EID: 70349451930     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/hrt.2009.172395     Document Type: Article

References (30)

1. Garrison RJ, Higgins MW, Kannel WB. Obesity and coronary heart disease. Curr Opin Lipidol 1996;4:199-202.
2. Tsai A, Cushman M, Rosamond W, et al. Cardiovascular risk factors and venous thromboembolism incidence: the longitudinal investigation of thromboembolism etiology. Arch Intern Med 2002;162:1182-1189 (Pubitemid 34522408)
3. Gruberg L, Weissman NJ, Waksman R, et al. The impact of obesity on the short-term and long-term outcomes after percutaneous coronary intervention: the obesity paradox? J Am Coll Cardiol 2002;39:578-584 (Pubitemid 34158151)
4. Gurm HS, Whitlow PL, Kip KE, BARI Investigators. The impact of body mass index on short- and long-term outcomes inpatients undergoing coronary revascularization. Insights from the bypass angioplasty revascularization investigation (BARI). J Am Coll Cardiol 2002;39:834-840
5. Gurm HS, Brennan DM, Booth J, et al. Impact of body mass index on outcome after percutaneous coronary intervention (the obesity paradox). Am J Cardiol 2002;90:42-45 (Pubitemid 34671201)
6. Powell BD, Lennon RJ, Lerman A, et al. Association of body mass index with outcome after percutaneous coronary intervention. Am J Cardiol 2003;91:472-476 (Pubitemid 36183574)
7. Minutello RM, Chou ET, Hong MK, et al. Impact of body mass index on in-hospital outcomes following percutaneous coronary intervention (report from the New York State Angioplasty Registry). Am J Cardiol 2004;93:1229-1232 (Pubitemid 38595675)
8. Ellis SG, Elliott J, Horrigan M, et al. Low-normal or excessive body mass index: newly identified and powerful risk factors for death and other complications with percutaneous coronary intervention. Am J Cardiol 1996;78:642-646 (Pubitemid 126658617)
9. Angiolillo DJ, Fernández-Ortiz A, Bernardo E, et al. Platelet aggregation according to body mass index in patients undergoing coronary stenting: should clopidogrel loading-dose be weight adjusted? J Invasive Cardiol 2004;16:169-174
10. Sibbing D, von Beckerath O, Schömig A, et al. Impact of body mass index on platelet aggregation after administration of a high loading dose of 600 mg of clopidogrel before percutaneous coronary intervention. Am J Cardiol 2007;100:203-205 (Pubitemid 47041981)
11. Feher G, Koltai K, Alkonyi B, et al. Clopidogrel resistance: role of body mass and concomitant medications. Int J Cardiol 2007;120:188-192 (Pubitemid 47042251)
12. Tamminen M, Lassila R, Westerbacka J, et al. Obesity is associated with impaired platelet-inhibitory effect of acetylsalicylic acid in nondiabetic subjects. Int J Obes Relat Metab Disord 2003;27:907-911 (Pubitemid 36918612)
13. Cohen HW, Crandall JP, Hailpern SM, et al. Aspirin resistance associated with HbA1c and obesity in diabetic patients. J Diabetes Complications 2008;22:224-228
14. Buonamici P, Marcucci R, Migliorini A, et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 2007;49:2312-2317 (Pubitemid 46891710)
15. Wang ZJ, Zhou YJ, Liu YY, et al. Impact of clopidogrel resistance on thrombotic events after percutaneous coronary intervention with drug-eluting stent. Thromb Res 2009;124:46-51.
16. Gum PA, Kottke-Marchant K, Welsh PA, et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003;41:961-965 (Pubitemid 36315537)
17. Ferro-Luzzi A, Garza C, Haas J, et al. Physical status: the use interpretation of anthropometry: report of a WHO Expert Committee.WHO Tech Rep Ser 1995;854:1-452.
18. Mauri L, Hsieh WH, Massaro JM, et al. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 2007;356:1020-1029 (Pubitemid 46376802)
19. Daly CA, Hildebrandt P, Bertrand M, et al, EUROPA investigators. Adverse prognosis associated with the metabolic syndrome in established coronary artery disease: data from the EUROPA trial. Heart 2007;93:1406-1411
20. Domanski MJ, Jablonski KA, Rice MM, et al, PEACE Investigators. Obesity and cardiovascular events in patients with established coronary disease. Eur Heart J 2006;27:1416-1422
21. Zhou BF, Cooperative Meta-Analysis Group of the Working Group on Obesity in China. Predictive values of body mass index and waist circumference for risk factors of certain related diseases in Chinese adults - study on optimal cut-off points of body mass index and waist circumference in Chinese adults. Biomed Environ Sci 2002;15:83-96.
22. Deurenberg P, Yap M, van Staveren WA. Body mass index and percent body fat: a meta analysis among different ethnic groups. Int J Obes Relat Metab Disord 1998;22:1164-1171 (Pubitemid 28548536)
23. Chang CJ, Wu CH, Chang CS, et al. Low body mass index but high percent body fat in Taiwanese subjects: implications of obesity cutoffs. Int J Obes Relat Metab Disord 2003;27:253-259
24. Razak F, Anand S, Vuksan V, et al, SHARE Investigators. Ethnic differences in the relationships between obesity and glucose-metabolic abnormalities: a cross-sectional population-based study. Int J Obes (Lond) 2005;29:656-667 (Pubitemid 40769487)
25. Razak F, Anand SS, Shannon H, et al. Defining obesity cut points in a multiethnic population. Circulation 2007;115:2111-2118 (Pubitemid 46659062)
26. Stevens J, Truesdale KP, Katz EG, et al. Impact of body mass index on incident hypertension and diabetes in Chinese Asians, American Whites, and American Blacks: the People's Republic of China Study and the Atherosclerosis Risk in Communities Study. Am J Epidemiol 2008;167:1365-1374 (Pubitemid 351770554)
27. Reiner A, Siscovick D, Rosendaal F. Hemostatic risk factors and arterial thrombotic disease. Thromb Haemost 2001;85:584-595 (Pubitemid 32293691)
28. Cushman M, Yanez D, Psaty B, et al. Association of fibrinogen and coagulation factors VII and VIII with cardiovascular risk factors in the elderly. Am J Epidemiol 1996;143:665-676
29. Panagiotakos DB, Pitsavos C, Yannakoulia M, et al. The implication of obesity and central fat on markers of chronic inflammation: the ATTICA study. Atherosclerosis 2005;183:308-315 (Pubitemid 41579282)
30. Sonnenberg G, Krakower G, Kissebah A. A novel pathway to the manifestations of metabolic syndrome. Obes Res 2004;12:180-186 (Pubitemid 41132540)